D. E. Shaw & Co., Inc. Akero Therapeutics, Inc. Transaction History

D. E. Shaw & Co., Inc.

$107 Billion
Q3 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 116,382 shares of AKRO stock, worth $3.73 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

116,382

Holding current value

$3.73 Million

% of portfolio

0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$21.45 - $29.34 $4.28 Million - $5.85 Million	-199,335 Reduced 63.14%	116,382 $3.34 Million
Q2 2024 Aug 14, 2024	SELL	$18.31 - $24.62 $1.67 Million - $2.25 Million	-91,408 Reduced 22.45%	315,717 $7.41 Million
Q1 2024 May 15, 2024	BUY	$17.76 - $31.18 $3.48 Million - $6.12 Million	196,165 Added 92.99%	407,125 $10.3 Million
Q4 2023 Feb 14, 2024	BUY	$11.38 - $50.33 $842,825 - $3.73 Million	74,062 Added 54.1%	210,960 $4.93 Million
Q3 2023 Nov 14, 2023	SELL	$41.19 - $52.25 $11.3 Million - $14.3 Million	-274,221 Reduced 66.7%	136,898 $6.92 Million
Q2 2023 Aug 14, 2023	BUY	$36.89 - $56.88 $1.59 Million - $2.45 Million	43,108 Added 11.71%	411,119 $19.2 Million
Q1 2023 May 15, 2023	BUY	$37.27 - $50.24 $2.76 Million - $3.73 Million	74,167 Added 25.24%	368,011 $14.1 Million
Q4 2022 Feb 14, 2023	BUY	$33.44 - $54.8 $8.52 Million - $14 Million	254,821 Added 653.0%	293,844 $16.1 Million
Q3 2022 Nov 14, 2022	BUY	$10.15 - $34.05 $287,782 - $965,419	28,353 Added 265.73%	39,023 $1.33 Million
Q2 2022 Aug 15, 2022	BUY	$8.0 - $15.01 $85,360 - $160,156	10,670 New	10,670 $101,000

Others Institutions Holding AKRO

# of Institutions

190

Shares Held

73.8M

Call Options Held

241K

Put Options Held

647K

View Full List

About Akero Therapeutics, Inc.

Ticker AKRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,417,600
Market Cap $1.49B
Description
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...

More about AKRO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account